First-Line Treatment for Patients with Advanced Renal Cell Carcinoma
The Pharma Data
APRIL 16, 2021
Food and Drug Administration in January 2021, and further applications are under review with health authorities globally. to 0.64; p <0.0001), the trial’s primary endpoint, compared to sunitinib. to 0.89; p=0.0010; median OS non-estimable for either arm). chair, International Kidney Cancer Coalition. months vs. 8.3
52 
Let's personalize your content